GeneDx Holdings

WGS

Market cap $4.73B

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.

Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of underserved healthcare stocks.

Sold 69,858 shares, reducing stake value by about $6.45 million Post-trade stake in GeneDx Holdings Corp: zero shares, $0 value The position previously comprised 1.9% of the fund's AUM as of the prior quarter

Sold 69,858 shares, reducing stake value by about $6.45 million Post-trade stake in GeneDx Holdings Corp: zero shares, $0 value The position previously comprised 1.9% of the fund's AUM as of the prior quarter

Added 120,000 shares of GeneDx Holdings, an increase valued at ~$12.93 million Post-trade stake: 120,000 shares worth $12.93 million as of September 30, 2025 GeneDx Holdings is not among Telemark Asset Management's top five positions by size

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: Stifel 2025 Healthcare Conference New York, New York Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET Jefferies Global Healthcare Conference London, UK Presentation: Wednesday, November 19 at 11:00 a.m. GMT Piper Sandler 37th Annual Healthcare Conference New York, New Yo.

GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Bryan Dechairo - Chief Operating Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Mark Massaro - BTIG, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division David Westenberg - Piper Sandler & Co., Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2025 Earnings Conference Call.

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.04 per share a year ago.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2025.